BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rausch CR, Jabbour EJ, Kantarjian HM, Kadia TM. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer 2020;126:1152-60. [PMID: 31794095 DOI: 10.1002/cncr.32606] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Duong VH. Approach to the Treatment of Philadelphia Chromosome-Negative B-cell ALL in Older Adults: Is Age Becoming just a Number? Curr Hematol Malig Rep 2023. [PMID: 36877337 DOI: 10.1007/s11899-023-00691-x] [Reference Citation Analysis]
2 Rausch CR, Kantarjian HM, Jabbour EJ. SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches. Clin Lymphoma Myeloma Leuk 2023:S2152-2650(23)00031-9. [PMID: 36872149 DOI: 10.1016/j.clml.2023.01.013] [Reference Citation Analysis]
3 Jabbour E, Jain N, Kantarjian H, O'brien S. Acute Lymphoblastic Leukemia. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm117.pub3] [Reference Citation Analysis]
4 Paul S, Short NJ. Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management. Curr Oncol Rep 2022. [PMID: 35141858 DOI: 10.1007/s11912-022-01220-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
5 Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ. The cure of leukemia through the optimist's prism. Cancer 2022;128:240-59. [PMID: 34614211 DOI: 10.1002/cncr.33933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
6 Wu SY, Short NJ, Nasr L, Dabaja BS, Fang PQ. Central Nervous System Prophylaxis and Treatment in Acute Leukemias. Curr Treat Options Oncol 2022;23:1829-44. [PMID: 36510037 DOI: 10.1007/s11864-022-01032-5] [Reference Citation Analysis]
7 Sheikh IN, Ragoonanan D, Franklin A, Srinivasan C, Zhao B, Petropoulos D, Mahadeo KM, Tewari P, Khazal SJ. Cardiac Relapse of Acute Lymphoblastic Leukemia Following Hematopoietic Stem Cell Transplantation: A Case Report and Review of Literature. Cancers (Basel) 2021;13:5814. [PMID: 34830969 DOI: 10.3390/cancers13225814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Pu X, Deng S, Yin N, Song L, He X, Xiao J. A Chinese Child Presented with Early T Cell Precursor Lymphoblastic Lymphoma. Case Rep Hematol 2021;2021:5561860. [PMID: 34621551 DOI: 10.1155/2021/5561860] [Reference Citation Analysis]
9 Jabbour E, Kantarjian H. Hyper-CVAD in 2021: Lessons Learned and New Approaches. Clinical Lymphoma Myeloma and Leukemia 2021;21:S82-S84. [DOI: 10.1016/s2152-2650(21)01221-0] [Reference Citation Analysis]
10 Ibrahim Fouad G, Ahmed KA. Neuroprotective Potential of Berberine Against Doxorubicin-Induced Toxicity in Rat's Brain. Neurochem Res 2021. [PMID: 34403065 DOI: 10.1007/s11064-021-03428-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Fang L, Fan S, Wu W, Li T, Zhu J. Ruthenium-catalyzed room-temperature coupling of α-keto sulfoxonium ylides and cyclopropanols for δ-diketone synthesis. Chem Commun (Camb) 2021;57:7386-9. [PMID: 34223842 DOI: 10.1039/d1cc02576g] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 2021;127:3381-9. [PMID: 34138471 DOI: 10.1002/cncr.33655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Jonas BA, Fisch SC, Rosenberg AS, Hoeg RT, Tuscano JM, Abedi M. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol 2021;96:E114-7. [PMID: 33476436 DOI: 10.1002/ajh.26105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 2021;127:2648-56. [PMID: 33793964 DOI: 10.1002/cncr.33529] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
15 Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 2021;127:2025-38. [PMID: 33740268 DOI: 10.1002/cncr.33469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Jabbour E, Kantarjian H. The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia 2021;21:63-65. [DOI: 10.1016/j.clml.2020.09.001] [Reference Citation Analysis]
17 Cook J, Litzow M. Advances in Supportive Care for Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep 2020;15:276-93. [PMID: 32607955 DOI: 10.1007/s11899-020-00585-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
18 Almanza-Huante E, Espinosa-Bautista K, Rangel-Patiño J, Demichelis-Gómez R. Comparison of Two Pediatric-Inspired Regimens to Hyper-CVAD in Hispanic Adolescents and Young Adults With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 2021;21:55-62.e2. [PMID: 32893130 DOI: 10.1016/j.clml.2020.07.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 2020;7:e523-33. [PMID: 32589978 DOI: 10.1016/S2352-3026(20)30144-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
20 Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol 2021;144:132-45. [PMID: 32392559 DOI: 10.1159/000508199] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]